This Week’s CGT News: Radiopharmaceutical Boosts CAR T

A targeted radiopharmaceutical improves CAR T activity in neuroblastoma models, engineered Tregs suppress allergic asthma, and new gene therapy platforms target MMA and the brain

In Vivo CAR T: A New Route to Treating Autoimmune Disease

How targeted in vivo CAR T delivery could pave the way for autoimmune disease treatments

Inside the Rise of circRNA

Circio CEO Erik Wiklund reflects on the discovery of human circular RNA and its evolution into a fast-moving therapeutic modality

This Week's CGT News: First Treg Therapy Approved

First Treg-based cell therapy approved, FDA advanced therapy office faces fresh turnover, and preclinical CAR T studies target rare blood cancers and glioblastoma

Roving Reporter Asks: How Are CGT Companies Rethinking Pricing and Reimbursement?

IBTV speaks with industry leaders at ARM’s Meeting on the Med 2026 to explore how cell and gene therapy companies are approaching pricing, reimbursement, and access as more potentially curative therapies reach patients

AI Framework Helps Identify New CAR T Target

A human-in-the-loop AI strategy helped narrow more than 10,000 candidates to a CAR T target now validated in mouse models

CAR T Cells Target TNF in Mouse Model of Rheumatoid Arthritis

A single infusion of engineered T cells degraded soluble TNF and produced durable disease control in mice

This Week's CGT News: World's First Solid Tumor CAR T Approved in China 

Why Early QC Planning Matters in Cell and Gene Therapy

Late-stage CMC setbacks often begin with early QC decisions that shape cell and gene therapy timelines, costs, and regulatory outcomes

Roving Reporter Asks: What Are Recent Breakthroughs Telling Us About the CGT Field’s Maturity?

IBTV speaks with industry leaders at ARM’s Meeting on the Med 2026 to explore what recent clinical, regulatory, and commercial milestones reveal about the next phase of cell and gene therapy